Related Experiment Video

Updated: May 9, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Update on novel therapies for pancreatic neuroendocrine tumors: 2013

Anastasios Dimou1, Kostas N Syrigos, Muhammad Wasif Saif

  • 1Department of Medicine, Albert Einstein Medical Center. Philadelphia, PA, USA.

JOP : Journal of the Pancreas
|July 13, 2013
PubMed

Insights

New treatments for pancreatic neuroendocrine tumors (pNETs) show promise. Novel somatostatin analogs, drug combinations like octreotide with everolimus, and targeted therapies are being investigated for advanced pNETs.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of neoplasms.
  • Current treatments for unresectable pNETs include everolimus, sunitinib, somatostatin analogs, and chemotherapy.

Purpose of the Study:

  • To review novel therapeutic strategies and drug combinations for advanced pancreatic neuroendocrine tumors presented at the ASCO Annual Meeting.

Main Methods:

  • Review of data from Phase I and Phase II clinical trials presented at the ASCO Annual Meeting.
  • Evaluation of novel somatostatin analogs, drug combinations, and targeted therapies.

Main Results:

  • Pasireotide, a novel somatostatin analog, demonstrated safety in a Phase I study.
  • The combination of octreotide with everolimus showed promising response rates and progression-free survival in a Phase II study.
  • The AKT inhibitor MK-2206 was well-tolerated with moderate efficacy.
  • Updated data on temsirolimus combined with bevacizumab in advanced pNETs were presented.

Conclusions:

  • Novel therapeutic agents and combinations are emerging for the management of advanced pancreatic neuroendocrine tumors.
  • Ongoing research is focused on improving treatment outcomes for patients with pNETs.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: